Total Payments
$188,645
2023 Payments
$11,886
Companies
5
Transactions
31
Medicare Patients
22
Medicare Billing
$1,427
Payment Breakdown by Category
Research$187,806 (99.6%)
Food & Beverage$773.15 (0.4%)
Education$66.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $187,806 | 10 | 99.6% |
| Food and Beverage | $773.15 | 19 | 0.4% |
| Education | $66.00 | 2 | 0.0% |
Payments by Type
Research
$187,806
10 transactions
General
$839.15
21 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valneva Austria GmbH | $114,945 | 6 | $0 (2022) |
| Eli Lilly and Company | $72,861 | 4 | $0 (2023) |
| Merz North America, Inc. | $753.74 | 16 | $0 (2023) |
| Allergan, Inc. | $60.95 | 3 | $0 (2021) |
| Galderma Laboratories, L.P. | $24.46 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $11,886 | 6 | Eli Lilly and Company ($11,722) |
| 2022 | $160,703 | 9 | Valneva Austria GmbH ($114,945) |
| 2021 | $15,998 | 12 | Eli Lilly and Company ($15,664) |
| 2018 | $27.37 | 2 | Allergan Inc. ($16.52) |
| 2017 | $30.56 | 2 | Allergan Inc. ($16.95) |
All Payment Transactions
31 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/06/2023 | Merz North America, Inc. | Xeomin (Biological) | Food and Beverage | In-kind items and services | $54.93 | General |
| Category: Musculoskeletal | ||||||
| 04/06/2023 | Merz North America, Inc. | Xeomin (Biological) | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: Musculoskeletal | ||||||
| 02/16/2023 | Merz North America, Inc. | Xeomin (Biological), Xeomin | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: Musculoskeletal | ||||||
| 01/25/2023 | Merz North America, Inc. | — | Education | In-kind items and services | $52.31 | General |
| 01/25/2023 | Merz North America, Inc. | — | Education | In-kind items and services | $13.69 | General |
| 01/10/2023 | Eli Lilly and Company | — | — | In-kind items and services | $11,721.89 | Research |
| Study: A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | ||||||
| 10/21/2022 | Merz North America, Inc. | Xeomin (Biological) | Food and Beverage | In-kind items and services | $245.36 | General |
| Category: Dermatology | ||||||
| 09/16/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $13,064.96 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 07/19/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $36,474.30 | Research |
| Study: AN OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE ANTIBODY PERSISTENCE AND LONG TERM SAFETY OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 06/27/2022 | Merz North America, Inc. | — | Food and Beverage | In-kind items and services | $38.06 | General |
| 04/19/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $2,385.45 | Research |
| Study: AN OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE ANTIBODY PERSISTENCE AND LONG TERM SAFETY OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 04/12/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 03/15/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $53,420.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 03/08/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $9,000.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 01/11/2022 | Eli Lilly and Company | — | — | In-kind items and services | $45,475.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 11/01/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $15,000.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 10/08/2021 | Eli Lilly and Company | — | — | In-kind items and services | $664.13 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 09/02/2021 | MERZ NORTH AMERICA, INC. | — | Food and Beverage | In-kind items and services | $129.88 | General |
| 06/30/2021 | MERZ NORTH AMERICA, INC. | — | Food and Beverage | In-kind items and services | $27.66 | General |
| 06/10/2021 | MERZ NORTH AMERICA, INC. | — | Food and Beverage | In-kind items and services | $18.61 | General |
| 05/26/2021 | MERZ NORTH AMERICA, INC. | — | Food and Beverage | In-kind items and services | $12.94 | General |
| 05/15/2021 | MERZ NORTH AMERICA, INC. | — | Food and Beverage | In-kind items and services | $34.46 | General |
| 04/12/2021 | MERZ NORTH AMERICA, INC. | — | Food and Beverage | In-kind items and services | $10.51 | General |
| 03/11/2021 | MERZ NORTH AMERICA, INC. | — | Food and Beverage | In-kind items and services | $27.27 | General |
| 02/25/2021 | MERZ NORTH AMERICA, INC. | — | Food and Beverage | In-kind items and services | $25.11 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | Valneva Austria GmbH | $76,085 | 4 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $61,139 | 3 |
| AN OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE ANTIBODY PERSISTENCE AND LONG TERM SAFETY OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | Valneva Austria GmbH | $38,860 | 2 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $11,722 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 2 | 22 | 22 | $44,132 | $1,427 |
Total Patients
22
Total Services
22
Medicare Billing
$1,427
Procedure Codes
2
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99284 | Emergency department visit, problem of high severity | Facility | 2021 | 11 | 11 | $23,732 | $841.05 | 3.5% |
| 99283 | Emergency department visit, moderately severe problem | Facility | 2021 | 11 | 11 | $20,400 | $585.97 | 2.9% |
About Dr. Sinikka Green, MD
Dr. Sinikka Green, MD is a Emergency Medicine healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1295789691.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sinikka Green, MD has received a total of $188,645 in payments from pharmaceutical and medical device companies, with $11,886 received in 2023. These payments were reported across 31 transactions from 5 companies. The most common payment nature is "" ($187,806).
As a Medicare-enrolled provider, Green has provided services to 22 Medicare beneficiaries, totaling 22 services with total Medicare billing of $1,427. Data is available for 1 year (2021–2021), covering 2 distinct procedure/service records.
Ad
Practice Information
- Specialty Emergency Medicine
- Location Austin, TX
- Active Since 05/20/2006
- Last Updated 06/01/2021
- Taxonomy Code 207P00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1295789691
Products in Payments
- Xeomin (Biological) $343.35
- BOTOX (Biological) $27.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Emergency Medicine Doctors in Austin
Dr. Arthur Abello, M.d, M.D
Emergency Medicine — Payments: $203,981
Emergency Medicine $203,981
Dr. Steven Conroy, Do, DO
Emergency Medicine — Payments: $44,003
Emergency Medicine $44,003
Dr. Nadav Mor, M.d, M.D
Emergency Medicine — Payments: $25,648
Emergency Medicine $25,648
Dr. Michael Zimmerman, M.d, M.D
Emergency Medicine — Payments: $13,554
Emergency Medicine $13,554
Saikrishna Balasubramanian, Md, MD
Emergency Medicine — Payments: $4,471
Emergency Medicine $4,471
Dr. Adam Barta, M.d, M.D
Emergency Medicine — Payments: $2,663
Emergency Medicine $2,663